Colleen Kusy
Stock Analyst at Baird
(1.64)
# 3,450
Out of 5,129 analysts
50
Total ratings
37.78%
Success rate
-2.33%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colleen Kusy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Downgrades: Neutral | $924 → $858 | $834.55 | +2.81% | 1 | Dec 18, 2025 | |
| NUVL Nuvalent | Maintains: Outperform | $112 → $158 | $103.15 | +53.17% | 3 | Nov 18, 2025 | |
| COGT Cogent Biosciences | Maintains: Neutral | $14 → $34 | $37.20 | -8.60% | 1 | Nov 11, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $50 → $52 | $22.29 | +133.29% | 13 | Oct 31, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Outperform | $17 → $24 | $9.16 | +162.01% | 5 | Oct 3, 2025 | |
| CLYM Climb Bio | Initiates: Outperform | $9 | $5.56 | +61.87% | 1 | Aug 15, 2025 | |
| ELVN Enliven Therapeutics | Maintains: Outperform | $40 → $52 | $28.01 | +85.65% | 3 | Jun 16, 2025 | |
| AGEN Agenus | Maintains: Neutral | $4 → $6 | $2.98 | +101.34% | 4 | Jun 4, 2025 | |
| OCS Oculis Holding AG | Maintains: Outperform | $37 → $41 | $28.60 | +43.38% | 4 | Mar 13, 2025 | |
| CHRS Coherus Oncology | Maintains: Outperform | $4 → $6 | $2.04 | +194.12% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $65 | $33.92 | +91.63% | 2 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $27 → $25 | $10.20 | +145.10% | 1 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $255 → $210 | $7.37 | +2,749.39% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $2.60 | +1,207.69% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $230 | $4.18 | +5,402.39% | 1 | Nov 2, 2021 |
argenx SE
Dec 18, 2025
Downgrades: Neutral
Price Target: $924 → $858
Current: $834.55
Upside: +2.81%
Nuvalent
Nov 18, 2025
Maintains: Outperform
Price Target: $112 → $158
Current: $103.15
Upside: +53.17%
Cogent Biosciences
Nov 11, 2025
Maintains: Neutral
Price Target: $14 → $34
Current: $37.20
Upside: -8.60%
Apellis Pharmaceuticals
Oct 31, 2025
Maintains: Outperform
Price Target: $50 → $52
Current: $22.29
Upside: +133.29%
Ocular Therapeutix
Oct 3, 2025
Maintains: Outperform
Price Target: $17 → $24
Current: $9.16
Upside: +162.01%
Climb Bio
Aug 15, 2025
Initiates: Outperform
Price Target: $9
Current: $5.56
Upside: +61.87%
Enliven Therapeutics
Jun 16, 2025
Maintains: Outperform
Price Target: $40 → $52
Current: $28.01
Upside: +85.65%
Agenus
Jun 4, 2025
Maintains: Neutral
Price Target: $4 → $6
Current: $2.98
Upside: +101.34%
Oculis Holding AG
Mar 13, 2025
Maintains: Outperform
Price Target: $37 → $41
Current: $28.60
Upside: +43.38%
Coherus Oncology
Dec 5, 2024
Maintains: Outperform
Price Target: $4 → $6
Current: $2.04
Upside: +194.12%
Nov 13, 2024
Maintains: Outperform
Price Target: $50 → $65
Current: $33.92
Upside: +91.63%
Mar 12, 2024
Reiterates: Outperform
Price Target: $27 → $25
Current: $10.20
Upside: +145.10%
Aug 5, 2022
Maintains: Outperform
Price Target: $255 → $210
Current: $7.37
Upside: +2,749.39%
Apr 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $2.60
Upside: +1,207.69%
Nov 2, 2021
Initiates: Outperform
Price Target: $230
Current: $4.18
Upside: +5,402.39%